IGNITE Firefighters' Health
Launched by STANFORD UNIVERSITY · Aug 20, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The IGNITE Firefighters' Health trial is looking into how a whole-food, plant-based diet—rich in vegetables, fruits, whole grains, and legumes—might help reduce cancer markers in firefighters. Researchers believe that changing what firefighters eat could positively impact their health, particularly concerning cancer and inflammation. The trial is currently recruiting participants, specifically active firefighters aged 18 and older who are willing to follow this type of diet and complete four clinic visits.
To be eligible for this study, participants must be active San Francisco firefighters with a willingness to adopt a plant-based diet. However, there are certain health conditions and recent medication use that could exclude someone from participating, such as being significantly overweight or having specific uncontrolled health issues like high cholesterol or diabetes. Participants can expect to follow a new diet and attend regular visits to help researchers gather important health information. This study aims to contribute valuable insights into the health of firefighters, which could lead to better dietary recommendations in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18+
- • Active SF firefighter
- • Willing to consume a plant-based diet (vegetables, fruit, whole grains, legumes, etc.)
- • Willing to complete 4 clinic visits
- Exclusion Criteria:
- • Weight \< 110 lb
- • BMI \>= 40
- • Self-reported uncontrolled hypercholesterolemia, hypertension or diabetes
- • Pregnant, lactating, or planning to become pregnant during the course of the study.
- * Use of any of the following drugs/supplements within the last 2 months:
- • systemic antibiotics, antifungals, antivirals, or antiparasitics (intravenous, intramuscular, or oral);
- • corticosteroids (intravenous, intramuscular, oral, nasal or inhaled);
- • cytokines;
- • methotrexate or immunosuppressive cytotoxic agents.
- • Chronic, clinically significant, or unstable (unresolved, requiring ongoing changes to medical management or medication) pulmonary, cardiovascular, gastrointestinal, hepatic or renal functional abnormality, as determined by medical history, Type 1 diabetes, dialysis
- • History of active cancer in the past 3 years except for squamous or basal cell carcinomas of the skin that have been medically managed by local excision
- • Unstable dietary history as defined by major changes in diet during the previous month, where the subject has eliminated or significantly increased a major food group in the diet.
- • Recent history of chronic excessive alcohol consumption defined as more than five 1.5-ounce servings of 80 proof distilled spirits, five 12-ounce servings of beer or five 5-ounce servings of wine per day; or \> 14 drinks/week.
- • Any confirmed or suspected condition/state of immunosuppression or immunodeficiency (primary or acquired) including HIV infection, multiple sclerosis, and Graves' disease.
- • Surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.
- • Regular/frequent use of smoking or chewing tobacco, e-cigarettes, cigars or other nicotine-containing products
- • Regular use of prescription opiate pain medication
About Stanford University
Stanford University is a prestigious academic institution renowned for its cutting-edge research and innovation in healthcare and medicine. As a clinical trial sponsor, Stanford leverages its extensive resources, including a collaborative network of world-class researchers and state-of-the-art facilities, to advance medical knowledge and improve patient care. The university is committed to conducting rigorous, ethical research that adheres to the highest standards of scientific integrity, fostering an environment where groundbreaking discoveries can translate into effective clinical applications. Through its clinical trials, Stanford aims to address critical health challenges and contribute to the development of novel therapies and treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Palo Alto, California, United States
Patients applied
Trial Officials
Christopher D Gardner, PhD
Principal Investigator
Stanford University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported